Lung Cancer Alliance-Kentucky/so.indiana Hails House Leadership On Lung Cancer Mortality Reduction Act
Congressman Harold Rogers (R-5th) and John Yarmuth (D-3rd) Join as Co-Sponsors
Louisville, KY [May 18, 2010] -- Today,
Lung Cancer Alliance-Kentucky/Southern Indiana (LCA-KY/So.IN)
acknowledged Congressman Harold Rogers (R-5th) and John Yarmuth (D-3rd)
for their leadership and support in establishing the first ever
multi-agency, comprehensive program targeted at lung cancer.
Entitled Lung Cancer Mortality Reduction Act,
H.R.2112 authorizes a five year program to reduce the mortality rate of
lung cancer which continues to be the number one cause of cancer
deaths both nationally and in the Commonwealth of Kentucky. Lung cancer
causes more deaths each year than breast, prostate, colon, kidney,
melanoma and liver cancers combined.
"Lung cancer is the leading cause of cancer deaths among
men and women. Anything that can be done to increase the parity in
funding for this deadly disease will be a significant advance in
reducing cancer morbidity and mortality,” said Congressman
Yarmuth. “We must make every effort to address lung cancer
comprehensively and not overlook the importance of earlier detection
and better disease management.”
In thanking the Congressmen for their support,
LCA-KY/So.IN Co-chair and lung cancer survivor, Nancy Alvey said,
“Representatives Rogers and Yarmuth are looked to as leaders on cancer
issues and their co-sponsorships of this breakthrough legislation are
very significant. We sincerely thank them and look forward to working
with them and others throughout the Commonwealth to continue to improve
lung cancer outcomes in Kentucky and beyond.”
The bill requires the Secretaries of Health and Human
Services, Defense and Veterans Affairs to combine forces on a
comprehensive, coordinated plan of action with funding authorized for
five years to accomplish the mortality reduction goal.
The National Cancer Institute (NCI) is required to
review its funding priorities in order to meet the lung cancer
mortality reduction goal and more national institutes are called on
directly to take part, including the National Institute of Heart, Lung
and Blood, the National Institute of Biomedical Imaging and
Bioengineering and the National Institute for Environmental Health
To insure accountability, the bill requires an annual
report to Congress and creates an oversight board composed of the three
Cabinet Secretaries and representatives from the fields of lung cancer
treatment, research and advocacy.
In addition, the bill directs the Secretaries of
Department of Defense (DOD) and Veterans’ Affairs (VA) to implement an
early detection and disease management program for military personnel
who are at high risk for lung cancer because of smoking or exposure to
carcinogens during active duty.
The bill also:
- Authorizes the Food and Drug Administration
(FDA) to create a new Lung Cancer Mortality Reduction drug program
with incentives for new treatments, targeted therapies, vaccines
and chemoprevention drugs for precancerous conditions.
- Requires the Centers for Disease Control and
Prevention to carry out an early disease research program targeted
at the high incidence and mortality rates among minority and
The bill includes specific authorizations of $75,000,000
for certain NIH agencies in FY10 and authorizes such additional sums
as may be necessary for all the cited agencies to accomplish the goal
for FY 2010 through FY2014.